The MarketWatch News Department was not involved in the creation of this content.-- Rezurock(R) (belumosudil tablets) now listed for public reimbursement, offering access to adult ...

Other CIBMTR presentations will include additional results from ACCESS study; a trial in progress update on the ACCELERATE trial (NCT06859424), a platform protocol for testing multiple PTCy-based ...

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 ...

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives ...

FDA has designated rexlemestrocel-L a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of chronic low back pain. RMAT designation provides all the benefits of Breakthrough and Fast ...

Introduction: The occurrence of monoclonal gammopathies (MG) and oligoclonal (two or more monoclonal proteins) gammopathies (OG) might be triggered by some factors, such as immune recovery following ...

In a landmark advancement for Indian healthcare, doctors at FMRI, Gurugram, have reported exceptional success in curing ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Prelude Therapeutics signs up to $935M deal with Incyte for a novel JAK2V617F inhibitor program to treat rare blood cancers.

Gurugram's FMRI doctors achieve remarkable success in treating children with Sickle Cell Disease through advanced stem cell ...

Merck & Co Inc <a href=" target="_blank">(MRK.N) has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients ...

Sanofi is pleased to announce that Quebec has added Rezurock® (belumosudil tablets) to the list of medications covered by the ...